More US employers dropping coverage for weight-loss drugs in 2027

A growing number of U.S. employers plan to exclude GLP-1 agonists for weight loss from their 2027 benefit plans, citing unsustainable cost trends. This follows similar moves announced earlier in the year. For practices, this means increased prior authorization denials and patient affordability conversations for drugs like Wegovy and Zepbound starting January 1. Update your patient financial counseling scripts and eligibility verification workflows now to include specific questions about GLP-1 coverage under the patient's 2027 plan.